ZEISS QUATERA 700 Power on Demand

PHOTON Results and Their Relation to DME Patients in Your Practice

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Joong Hun Kim, MD

PULSAR Results and Their Relation to nAMD Patients in Your Practice

In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction

Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Two people sit at a table. Their hands are visible, as are computers, pencils, notebooks, clipboards and documents. Concept image for business merger, licensing partnership, work collaboration, commercialisation throughout Europe, Re-Vana Therapeutics and Boehringer Ingelheim ocular eye drug therapy. Image credit: ©NAMPIX – stock.adobe.com

Biomarkers of microvascular retinal perfusion indicating coronary heart disease

The companies will focus their joint effort on extended-release therapies for ocular disease

The retina undergoing fundus imaging. Concept image for retinal imgaging, OCT, CA, cardiac angiography, optical coherence tomography and biomarkers. Image credit: ©Panama – stock.adobe.com

Opus Genetics, Global RDH12 Alliance announce new collaboration

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

Related Content

Kassi Filkins

PHOTON Results and Their Relation to DME Patients in Your Practice

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Joong Hun Kim, MD

PULSAR Results and Their Relation to nAMD Patients in Your Practice

Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Biomarkers of microvascular retinal perfusion indicating coronary heart disease

The companies will focus their joint effort on extended-release therapies for ocular disease